# US 2021/0277003 A1 · Oga inhibitor compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277003 A1
- Document ID: US20210277003A1
- Status: Published application
- Kind: A1
- Application number: 17/253,505
- Filed: 2019-06-20
- Published: 2021-09-09
- Earliest claimed: 2018-06-21
- Applicants: Janssen Pharmaceutica NV
- Inventors: José Manuel Bartolomé-Nebreda; Andrés Avelino Trabanco-Suárez; Carolina Martinez Lamenca; Joseph Elisabeth Leenaerts; Daniel Oehlrich; Petrus Jacobus Johannes Antonius Buijnsters; Adriana Ingrid Velter; Yves Emiel Maria Van Roosbroeck
- Web page: https://patentgrep.com/patent/US20210277003A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

## Claims

### Claim 1

A compound of Formula (I)
or a tautomer or a stereoisomeric form thereof, wherein
R1 is selected from the group consisting of C1-6alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, —CN, —OC1-3alkyl, —OH, —SO2NR5aR6a, and C3-6cycloalkyl optionally substituted with one or more independently selected halo substituents; C1-6alkyl substituted with oxetanyl; and C1-6alkyl wherein two geminal hydrogens are replaced by oxetanylidene; wherein R5a and R6a are each independently selected from the group consisting of hydrogen and C1-3alkyl; with the proviso that a —OC1-3alkyl or —OH substituent, when present, is at least two carbon atoms away from the nitrogen atom of the 1H-pyrrolo[3.2-c]pyridine;
R2, R3 and R5 are each independently selected from the group consisting of hydrogen, halo and C1-3alkyl;
R4 is a monovalent radical selected from the group consisting of (a), (b), (c), and (d):
wherein
R1a, R2a, R1b, and R2b are each independently selected from the group consisting of halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, C1-3alkyloxy, monohaloC1-3alkyloxy, polyhaloC1-3alkyloxy, and C3-6cycloalkyl;
R3a is selected from the group consisting of hydrogen, halo, —C(O)—OC1-3alkyl, —C(O)—NR′R″, and —N(R′″)—C(O)—C1-3alkyl;
R4a is selected from the group consisting of hydrogen, halo, —CN, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, —C(O)—OC1-3alkyl, —C(O)—NR′R″, —N(R′″)—C(O)—C1-3alkyl, and Het;
with the proviso that R3a and R4a are not simultaneously —C(O)—OC1-3alkyl, —C(O)—NR′R″, or —N(R′″)—C(O)—C1-3alkyl;
R′ and R″ are each independently selected from the group consisting of hydrogen and C1-3alkyl; or R′ and R″ together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;
R′″ is selected from the group consisting of hydrogen and C1-3alkyl;
Het is pyrazolyl or imidazolyl, optionally substituted with one or more independently selected C1-3alkyl substituents;
X1 and X2 are each independently selected from N and CH, with the proviso that at least one of X1 or X2 is N;
R1c, R2c, and R1d are each independently selected from the group consisting of halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, C1-3alkyloxy, monohaloC1-3alkyloxy, polyhaloC1-3alkyloxy, and C3-6cycloalkyl;
X3 represents CH or N;
and each of the rings represented by
form
(i) a 5- or 6-membered unsaturated heterocycle having one, two or three heteroatoms each independently selected from nitrogen and oxygen, and which is optionally substituted with one or more substituents, each independently selected from halo, C1-3alkyl and oxo; or
(ii) an aromatic heterocycle having one, two or three heteroatoms each independently selected from nitrogen, oxygen, and sulfur, and which is optionally substituted with one or more substituents, each independently selected from halo, —CN, C1-3alkyl, monohaloC1-3alkyl, and polyhaloC1-3alkyl;
or a pharmaceutically acceptable addition salt or a solvate thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
R1 is selected from the group consisting of C1-6alkyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, —CN, —OC1-3alkyl, —OH, —SO2NR5aR6a, and C3-6cycloalkyl optionally substituted with one, two or three independently selected halo substituents; C1-6alkyl substituted with oxetanyl; and C1-6alkyl wherein two geminal hydrogens are replaced by oxetanylidene; wherein R5a and R6a are each independently selected from the group consisting of hydrogen and C1-3alkyl; with the proviso that a —OC1-3alkyl or —OH substituent, when present, is at least two carbon atoms away from the nitrogen atom of the 1H-pyrrolo[3.2-c]pyridine;
R2, R3 and R5 are each independently selected from the group consisting of hydrogen, halo and C1-3alkyl;
R4 is a monovalent radical selected from the group consisting of (a), (b), (c), and (d), wherein R1a, R2a, R1b, and R2b are each independently selected from the group consisting of halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, and C3-6cycloalkyl;
R3a is selected from the group consisting of hydrogen, halo, —C(O)—NR′R″, and —N(R′″)—C(O)—C1-3alkyl;
R4a is selected from the group consisting of hydrogen, halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, —C(O)—OC1-3alkyl, —C(O)—NR′R″, —N(R′″)—C(O)—C1-3alkyl, and Het; with the proviso that R3a and R4a are not simultaneously —C(O)—OC1-3alkyl, —C(O)—NR′R″, or —N(R′″)—C(O)—C1-3alkyl;
R′ and R″ are each independently selected from the group consisting of hydrogen and C1-3alkyl; or R′ and R″ together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl;
R′″ is selected from the group consisting of hydrogen and C1-3alkyl;
Het is pyrazolyl or imidazolyl, optionally substituted with one or more independently selected C1-3alkyl substituents;
X1 and X2 are each independently selected from N and CH, with the proviso that at least one of X1 or X2 is N;
R1c, R2c, and R1d each independently represent halo or C1-3alkyl;
X3 represents CH or N;
and each of the rings represented by
form
(i) a 5- or 6-membered unsaturated heterocycle having one, two or three heteroatoms each independently selected from nitrogen and oxygen, and which is optionally substituted with one or two substituents, each independently selected from halo, C1-3alkyl and oxo; or
(ii) an aromatic heterocycle having one, two or three heteroatoms each independently selected from nitrogen and oxygen, and which is optionally substituted with one or two substituents, each independently selected from C1-3alkyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 is selected from the group consisting of C1-6alkyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, and C3-6cycloalkyl optionally substituted with one, two or three independently selected halo substituents; C1-6alkyl substituted with oxetanyl; and C1-6alkyl wherein two geminal hydrogens are replaced by oxetanylidene;
R2, R3 and R5 are each independently selected from the group consisting of hydrogen, halo and C1-3alkyl;
R4 is a monovalent radical selected from the group consisting of (a), (b), (c), and (d), wherein R1a, R2a, R1b, and R2b are each independently selected from the group consisting of halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, and C3-6cycloalkyl;
R3a is selected from the group consisting of hydrogen, halo, and —C(O)—NR′R″;
R4a is selected from the group consisting of hydrogen, halo, C1-3alkyl, monohaloC1-3alkyl, polyhaloC1-3alkyl, —C(O)—OC1-3alkyl, —C(O)—NR′R″, —N(R′″)—C(O)—C1-3alkyl, and Het; with the proviso that R3a and R4a are not simultaneously —C(O)—OC1-3alkyl, —C(O)—NR′R″, or —N(R′″)—C(O)—C1-3alkyl;
R′ and R″ are each independently selected from the group consisting of hydrogen and C1-3alkyl; or R′ and R″ together with the nitrogen atom to which they are attached form a heterocyclyl ring selected from the group consisting of pyrrolidinyl, and morpholinyl;
R′″ is selected from the group consisting of hydrogen and C1-3alkyl;
Het is pyrazolyl or imidazolyl, optionally substituted with one or more independently selected C1-3alkyl substituents;
X1 and X2 are each independently selected from N and CH, with the proviso that at least one of X1 or X2 is N;
R1c, R2c, and R1d each independently represent halo or C1-3alkyl;
X3 represents CH or N;
and each of the rings represented by
form
(i) a 5- or 6-membered unsaturated heterocycle having one, two or three heteroatoms each independently selected from nitrogen and oxygen, and which is optionally substituted with one or two substituents, each independently selected from halo, C1-3alkyl and oxo; or
(ii) an aromatic heterocycle having one, two or three heteroatoms each independently selected from nitrogen and oxygen, and which is optionally substituted with one or two substituents, each independently selected from C1-3alkyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1 is C1-6alkyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, and C3-6cycloalkyl optionally substituted with one, two or three independently selected halo substituents or R1 is C1-6alkyl substituted with oxetanyl or C1-6alkyl wherein two geminal hydrogens are replaced by oxetanylidene.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R2 and R3 are each independently selected from hydrogen and fluoro.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R5 is hydrogen, fluoro or methyl.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a prophylactically or a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A process for preparing a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier with a prophylactically or a therapeutically effective amount of a compound according to claim 1.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method of preventing or treating a disorder selected from the group consisting of tauopathy, in particular a tauopathy selected from the group consisting of Alzheimer's disease, progressive supranuclear palsy, Down's syndrome, frontotemporal lobe dementia, frontotemporal dementia with Parkinsonism-17, Pick's disease, corticobasal degeneration, and agryophilic grain disease; or a neurodegenerative disease accompanied by a tau pathology, in particular a neurodegenerative disease selected from amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations, comprising administering to a subject in need thereof, a prophylactically or a therapeutically effective amount of a compound according to claim 1.

### Claim 12

(canceled)
